Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited therapeutic options, and there is a huge unmet need for new therapies. A growing body of evidence suggests that the histone deacetylase (HDAC) family of transcriptional corepressors has emerged as crucial mediat...
Main Authors: | Martina Korfei, Poornima Mahavadi, Andreas Guenther |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/10/1626 |
Similar Items
-
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
by: Monica Phimmachanh, et al.
Published: (2020-10-01) -
Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
by: Fengyi Guo, et al.
Published: (2022-11-01) -
Histone Acetylation Changes in Plant Response to Drought Stress
by: Shuang Li, et al.
Published: (2021-09-01) -
The Role of Histone Acetylation and the Microbiome in Phytochemical Efficacy for Cardiovascular Diseases
by: Levi W. Evans, et al.
Published: (2020-06-01) -
Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis
by: Lotte Nijhuis, et al.
Published: (2019-02-01)